000186724 001__ 186724
000186724 005__ 20240229154903.0
000186724 0247_ $$2doi$$a10.1016/j.eururo.2022.12.003
000186724 0247_ $$2pmid$$apmid:36631351
000186724 0247_ $$2ISSN$$a0302-2838
000186724 0247_ $$2ISSN$$a1421-993X
000186724 0247_ $$2ISSN$$a1873-7560
000186724 037__ $$aDKFZ-2023-00076
000186724 041__ $$aEnglish
000186724 082__ $$a610
000186724 1001_ $$0P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aAlbers, Peter$$b0$$eLast author$$udkfz
000186724 245__ $$aRe: Association of Prostate-specific Antigen Screening Rates with Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities: Prostate cancer screening needs not only to be well meant but also well done.
000186724 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2023
000186724 3367_ $$2DRIVER$$aarticle
000186724 3367_ $$2DataCite$$aOutput Types/Journal article
000186724 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1686568366_27237$$xEditorial
000186724 3367_ $$2BibTeX$$aARTICLE
000186724 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000186724 3367_ $$00$$2EndNote$$aJournal Article
000186724 500__ $$a#LA:C130# / 2023 Apr;83(4):369-370
000186724 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000186724 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000186724 773__ $$0PERI:(DE-600)1482253-2$$a10.1016/j.eururo.2022.12.003$$gp. S0302283822028524$$n4$$p369-370$$tEuropean urology$$v83$$x0302-2838$$y2023
000186724 909CO $$ooai:inrepo02.dkfz.de:186724$$pVDB
000186724 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f84639cbc39bc20ecda8d00e6de97578$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000186724 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000186724 9141_ $$y2023
000186724 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-22
000186724 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-22
000186724 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-22
000186724 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-10-21$$wger
000186724 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR UROL : 2022$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000186724 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bEUR UROL : 2022$$d2023-10-21
000186724 9202_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000186724 9201_ $$0I:(DE-He78)C130-20160331$$kC130$$lPersonalisierte Früherkennung des Prostatakarzinoms$$x0
000186724 980__ $$ajournal
000186724 980__ $$aVDB
000186724 980__ $$aI:(DE-He78)C130-20160331
000186724 980__ $$aUNRESTRICTED